Gender Difference and PANSS Score of Paranoid Schizophrenia Using Risperidone

Abstract

Recently many focus study of schizophrenia on gender are about onset and reducing the severity of illness. Males typically experience a much earlier age of onset, make up a larger proportion of clinical cases, and are more likely to have primary negative symptoms that are associated with chronic course and poor outcome. These study used the standard mental state examination of Psychiatry Department of University of North Sumatera, and SCID (Structured Clinical Interview for DSM-IV) that had been translated in Indonesian. The psychotic symptoms were rated by PANSS, using the total PANSS score. All subjects was examined until 8 weeks for each week. From the 80 total subjects, the mean age of the study for males and females was 29,42±5,53 for males and 30,80±5,64, respectively. The onset was 25,60±6,86 and 26,98±7,44. There was significant difference between gender and PANSS total scores in week 1 until 6 (p<0,05) where males was higher than females, but no differences in other weeks. The decrease of total PANSS per week showed significant difference (p<0,05) in week 1,2, 7 and 8, but not significant in other week. No significant difference (p?0,05) of total PANSS score between gender, before and after using risperidone. The difference respons percentage between male and female was not significant (p?0,05). In these study, the mean dosis of risperidone for male and female respectively was 4,008±0,141 and 4,083±0,215. There was some significant difference between gender from the psychopathology perspective in schizophrenia using risperidone.

Keywords: gender, PANSS score, risperidone